Outlook Therapeutics, Inc. (NASDAQ:OTLK) Given Average Rating of “Moderate Buy” by Brokerages

Outlook Therapeutics, Inc. (NASDAQ:OTLK) has been assigned an average rating of “Moderate Buy” from the eight ratings firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $45.55.

A number of research analysts recently weighed in on the stock. HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Outlook Therapeutics in a research note on Thursday, August 15th. Chardan Capital restated a “buy” rating and issued a $53.00 price objective on shares of Outlook Therapeutics in a research report on Friday, August 16th.

Outlook Therapeutics Stock Down 1.4 %

Shares of NASDAQ:OTLK opened at $7.17 on Friday. The firm’s 50 day simple moving average is $7.66 and its two-hundred day simple moving average is $8.04. Outlook Therapeutics has a 1-year low of $4.00 and a 1-year high of $29.20.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in OTLK. AQR Capital Management LLC bought a new stake in shares of Outlook Therapeutics in the second quarter worth about $75,000. Squarepoint Ops LLC bought a new position in Outlook Therapeutics during the second quarter valued at approximately $232,000. Susquehanna Fundamental Investments LLC purchased a new position in Outlook Therapeutics during the 2nd quarter valued at approximately $303,000. LVW Advisors LLC bought a new stake in Outlook Therapeutics in the 2nd quarter worth approximately $352,000. Finally, Rosalind Advisors Inc. raised its holdings in shares of Outlook Therapeutics by 44.3% during the 2nd quarter. Rosalind Advisors Inc. now owns 450,000 shares of the company’s stock worth $3,321,000 after acquiring an additional 138,225 shares in the last quarter. Institutional investors own 11.20% of the company’s stock.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.